ERBB2 and cancer: Cancer registry data from the SEER program reported fairly similar proportions from the U.S. for the period 2016–2020: 4% for HER2+/HR−, 69% for HER2–/HR+, 10% for TNBC, and 10% for HR+/HER2+ (20).